A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE)

Journal of Hepatology

Volumn 45, Issue 2, 2006, Pages 204-213

  Silva, Marcelo ^a   Poo, Jorge ^b   Wagner, Frank ^c   Jackson, Mary ^d   Cutler, David ^d   Grace, Michael ^d   Bordens, Ronald ^d   Cullen, Connie ^d   Harvey, Joann ^d   Laughlin, Mark ^d  

^a UNIVERSIDAD AUSTRAL   (Argentina)

^b LIVER RESEARCH UNIT   (Mexico)

^c Clinical Research   (Germany)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Chronic hepatitis C infection; Peginterferon alfa 2a; Peginterferon alfa 2b; Pegylated interferon; Ribavirin

Indexed keywords

MESSENGER RNA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ABDOMINAL PAIN; ADULT; ANEMIA; ANOREXIA; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BACKACHE; BILIARY TRACT DISEASE; BLOOD LEVEL; BLOOD TOXICITY; BREAST DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DYSMENORRHEA; ERYTHEMA MULTIFORME; ERYTHROCYTE DISORDER; FATIGUE; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEMATOCRIT; HEMOGLOBINOPATHY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; LIVER TOXICITY; LYMPHATIC SYSTEM DISEASE; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; UPREGULATION;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; DRUG CARRIERS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMERASE CHAIN REACTION; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33745713376     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2006.03.008     Document Type: Article

References (22)

1. Caselmann W.H., and Alt M. Hepatitis C virus infection as a major risk factor for hepatocellular carcinoma. J Hepatol 24 (1996) 61-66
2. El-Serag H.B., and Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340 (1999) 745-750
3. Wong J.B., McQuillan G.M., McHutchison J.G., and Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 90 (2000) 1562-1569
4. National Institutes of Health. NIH Consensus Statement on management of hepatitis C: 2002. NIH Consens State Sci Statements 2002;19:1-46.
5. Samuel C.E. Antiviral actions of interferons. Clin Microbiol Rev 14 (2001) 778-809 table of contents
6. Kalvakolanu D.V., and Borden E.C. An overview of the interferon system: signal transduction and mechanisms of action. Cancer Invest 14 (1996) 25-53
7. Kerr I.M., Costa-Pereira A.P., Lillemeier B.F., and Strobl B. Of JAKs, STATs, blind watchmakers, jeeps and trains. FEBS Lett 546 (2003) 1-5
8. Delgado C., Francis G.E., and Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 9 (1992) 249-304
9. Inada Y., Furukawa M., Sasaki H., Kodera Y., Hiroto M., Nishimura H., et al. Biomedical and biotechnological applications of PEG- and PM-modified proteins. Trends Biotechnol 13 (1995) 86-91
10. Grace M.J., and Cutler D. Pegylating IFNs at his-34 improves the in vitro antiviral activity through the JAK/STAT pathway. Antivir Chem Chemother 15 (2004) 287-297
11. Wang Y.S., Youngster S., Bausch J., Zhang R., McNemar C., and Wyss D.F. Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry 39 (2000) 10634-10640
12. Grace M., Youngster S., Gitlin G., Sydor W., Xie L., Westreich L., et al. Structural and biological characterization of pegylated recombinant IFN-alpha2b. [with Correction to Figure 1, J Interferon Cytokine Res 2002:22:404]. J Interferon Cytokine Res 21 (2001) 1103-1115
13. Monkarsh S.P., Ma Y., Aglione A., Bailon P., Ciolek D., DeBarbieri B., et al. Positional isomers of monopegylated interferon alpha-2a: isolation, characterization, and biological activity. Anal Biochem 247 (1997) 434-440
14. Bailon P., Palleroni A., Schaffer C.A., Spence C.L., Fung W.J., Porter J.E., et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon-alpha-2a for the treatment of hepatitis C. Bioconjug Chem 12 (2001) 195-202
15. Roberts M.J., and Harris J.M. Attachment of degradable poly(ethylene glycol) to proteins has the potential to increase therapeutic efficacy. J Pharm Sci 87 (1998) 1440-1445
16. Foser S., Schacher A., Weyer K.A., Brugger D., Dietel E., Marti S., et al. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS). Protein Expr Purif 30 (2003) 78-87
17. Grace M., Lee S., Bradshaw S., Chapman J., Spond J., Cox S., et al. Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway. J Biol Chem 280 (2005) 6327-6336
18. Obenauer-Kutner L.J., Jacobs S.J., Kolz K., Tobias L.M., and Bordens R.W. A highly sensitive electrochemiluminescence immunoassay for interferon alfa-2b in human serum. J Immunol Methods 206 (1997) 25-33
19. Xie L., Cullen C., Bradshaw S., DeLorenzo M., and Grace M. Biological characterization of pegylated interferons: a case study. In: Smales M., and James D.G. (Eds). Therapeutic proteins: methods and protocols (2005), Humana Press, Totowa, NJ 319-336
20. Brassard D.L., Delorenzo M.M., Cox S., Leaman D.W., Sun Y., Ding W., et al. Regulation of gene expression by pegylated IFN-alpha2b and IFN-alpha2b in human peripheral blood mononuclear cells. J Interferon Cytokine Res 24 (2004) 455-469
21. Joliffe I.T., and Morgan B.J. Principal component analysis and exploratory factor analysis. Stat Methods Med Res 1 (1992) 69-95
22. Peck-Radosavljevic M., Schmid M., Formann E., Homoncik M., Datz C., Gangl A., et al. Hemopoiesis suppression with different peylated and nonpegylated interferon alfa regimens for chronic hepatitis C. Gastroenterology 128 Suppl. 2 (2005) [Poster presentation S1563]